Axsome Therapeutics (AXSM)
(Real Time Quote from BATS)
$115.93 USD
-2.70 (-2.28%)
Updated Sep 19, 2025 03:32 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AXSM 115.93 -2.70(-2.28%)
Will AXSM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?
Axsome Shares Up 20% in a Month: How Should You Play the Stock?
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings
Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates
Other News for AXSM
Technical picture remains unchanged for AXSM after it rises 1.72% on September 18
Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
AXSM's price rises by 2.21% on September 18, though its technical setup remains stable.
Fairmount Funds Management LLC Increases Stake in Dianthus Therapeutics Inc
Is AXSM heading for a slide? New Downtrend shows up after sliding 2.29%